A multicenter retrospective study in Italy evaluated the effectiveness of bimekizumab, a monoclonal antibody targeting Interleukin-17 A and F, in patients with moderate-to-severe plaque psoriasis. Conducted across 19 referral hospitals, the study included 237 patients treated with bimekizumab over a one-year period. Results showed significant improvement in psoriasis area and severity index (PASI) scores, with 43.3% of patients achieving complete skin clearance at week 4 and 75.4% at week 16. Importantly, 86.8% of patients reported no negative impact on their quality of life by week 16, and adverse events were generally mild, with oral candidiasis being the most common.

The study suggests that bimekizumab is effective and well-tolerated in real-world settings, aligning with findings from phase-III clinical trials. These results underscore the potential of bimekizumab as a valuable treatment option for patients with moderate-to-severe plaque psoriasis, highlighting its role in improving both skin symptoms and quality of life.

Reference: Gargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med (Lausanne). 2023 Aug 8;10:1243843. doi: 10.3389/fmed.2023.1243843. PMID: 37614958; PMCID: PMC10442506.